-transparent.png){kind=logo}
A hepatitis B vaccine which has been prepared from HBsAg and HBeAg positive human plasma and which consists of purified HBsAg in an alum suspension was investigated for safety and immunogenicity in a clinical trial. Twenty-three anti-HBs seronegative volunteers received three injections each of 40 micrograms HBsAg intramuscularly. No rise in serum transaminase activities occurred during the follow-up period, and none of the volunteers developed clinical signs related to viral hepatitis. Only minor side reactions like burning or reddening at the site of injection were reported by the volunteers. 100% seroconversion occurred within 150 days after first vaccination. The subsequent two vaccinations caused a strong booster effect.
R Kaufmann, and
A W Mondorf, and
H Uthemann, and
H Bauer, and
A M Prince
May 2010,
Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
R Kaufmann, and
A W Mondorf, and
H Uthemann, and
H Bauer, and
A M Prince
January 1993,
Communicable disease report. CDR weekly,
R Kaufmann, and
A W Mondorf, and
H Uthemann, and
H Bauer, and
A M Prince
November 1987,
Clinical and experimental immunology,
R Kaufmann, and
A W Mondorf, and
H Uthemann, and
H Bauer, and
A M Prince
June 1995,
Lancet (London, England),
R Kaufmann, and
A W Mondorf, and
H Uthemann, and
H Bauer, and
A M Prince
April 1991,
The Journal of infectious diseases,
R Kaufmann, and
A W Mondorf, and
H Uthemann, and
H Bauer, and
A M Prince
January 2000,
Scandinavian journal of infectious diseases,
R Kaufmann, and
A W Mondorf, and
H Uthemann, and
H Bauer, and
A M Prince
May 1989,
Lancet (London, England),
R Kaufmann, and
A W Mondorf, and
H Uthemann, and
H Bauer, and
A M Prince
November 2016,
Journal of gastroenterology,
R Kaufmann, and
A W Mondorf, and
H Uthemann, and
H Bauer, and
A M Prince
September 2023,
Vaccines,
R Kaufmann, and
A W Mondorf, and
H Uthemann, and
H Bauer, and
A M Prince
May 1990,
American journal of public health,
